Seattle-based Umoja Biopharma has raised a $100 million Series C round. With the funding, announced Tuesday, Umoja wants to ...

It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.

Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.

Its lead candidate Tune-401, which aims to repress viral DNA that contributes to infection, has entered into clinical trials in New Zealand and Hong Kong.

A Durham biotech firm founded on technology built at Duke University has raised $175 million to fund clinical trials of its ...

Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest ...

Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution ...

DURHAM, N.C. (WNCN) – Authorities are searching for a gunman after Durham police said a man was found shot to death in his car early Monday morning. According to the Durham Police Department, officers ...

The biggest cause of frustration for guitar players? The struggle to stay in tune is real, but there are ways to make things easier When you purchase through links on our site, we may earn an ...